Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers. On the heels of auspicious clinical trial results, in June 2019, San Diego-based Oncternal Therapeutics completed a reverse merger with then publicly traded Tennessees firm GTx. At deal close, Oncternal changed its ticker symbol on the Nasdaq Capital Market to ONCT. . With the focuse on drug development on promising biological pathways, the pipeline includes four investigational product candidates: (1) Zilovertamab, a monoclonal antibody that inhibits the ROR1 protein expressed in multiple hematologic and solid malignancies, in Phase 2 development with a lead indication of mantle cell lymphoma (MCL) (2)ONCT-216, a small molecule that inhibits ETS-family oncoproteins, which have been implicated in multiple hematological and solid malignancies, in Phase 2 development with a lead indication of Ewing sarcoma, a rare pediatric cancer. (3) ONCT-808, an autologous CAR-T cell therapy that targets ROR1, as a targeted treatment for patients with multiple hematologic and solid malignancies, currently in preclinical development and (4) ONCT-534, a Dual-Action Androgen Receptor Inhibitor (DAARI), as a targeted therapy for advanced prostate cancer resistant to available therapies, currently in preclinical development
